3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Withdrawn
1
Recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
4
Breast
4
Tumor-Agnostic
3
Thoracic
3
Gynecologic
2
Genitourinary
2
Other
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Endometrial Neoplasms
15
Ovarian Neoplasms
5
Uterine Cervical Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Breast Neoplasms
4
Endometrial Hyperplasia
3
Pancreatic Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Kidney Neoplasms
2
Fallopian Tube Neoplasms
2
Colonic Neoplasms
2
Waldenstrom Macroglobulinemia
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sezary Syndrome
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pleural Effusion, Malignant
1
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Interventions
Paclitaxel
28
Carboplatin
28
pembrolizumab
25
Bevacizumab
14
liposomal doxorubicin
12
Cisplatin
11
Gemcitabine
10
Radiotherapy
8
Drug Therapy
8
Cyclophosphamide
8
Blood Specimen Collection
8
Topotecan
7
Nivolumab
7
olaparib
6
Doxorubicin
6
niraparib
5
Therapeutics
5
Dexamethasone
5
pertuzumab
4
pazopanib
4
lenvatinib
4
fludarabine
4
cemiplimab
4
atezolizumab
4
Trastuzumab
4
Surveys and Questionnaires
4
Psychiatric Rehabilitation
4
Polymerase Chain Reaction
4
Fulvestrant
4
Docetaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
Metformin
×
Gynecologic
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn